SCHEMBL26123770

SCHEMBL26123770

C[C@H]1CC[C@@H](C(=O)O)CN1C(=O)Cc1ccc(-c2ncccn2)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
HPGD P15428 2/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GLA P06280 1/20 0.40
S1PR5 Q9H228 5/20 0.38
CHRM2 P08172 3/20 0.38
GHSR Q92847 3/20 0.38
CYP3A4 P08684 1/20 0.38
HTR2B P41595 1/20 0.38
KCNH2 Q12809 1/20 0.38
SLC6A7 Q99884 1/20 0.37
S1PR1 P21453 4/20 0.36
S1PR4 O95977 1/20 0.36
S1PR3 Q99500 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31367820 0.90 SMN1; SMN2 (0.40) SMN1; SMN2HPGDTSHRALDH1A1GLA
SCHEMBL26122090 0.90 SMN1; SMN2 (0.40) SMN1; SMN2HPGDTSHRALDH1A1GLA
SCHEMBL26122082 0.88 SMN1; SMN2 (0.46) SMN1; SMN2HPGDTSHRL3MBTL1ALDH1A1
SCHEMBL26123319 0.88 JAK1 (0.42) SMN1; SMN2HPGDTSHRL3MBTL1ALDH1A1
SCHEMBL26122371 0.87 SMN1; SMN2 (0.54) SMN1; SMN2HPGDTSHRL3MBTL1ALDH1A1
SCHEMBL26122147 0.86 SMN1; SMN2 (0.43) SMN1; SMN2HPGDTSHRL3MBTL1ALDH1A1
SCHEMBL31367825 0.85 EIF2AK4 (0.41) SMN1; SMN2HPGDS1PR5CHRM2S1PR1
SCHEMBL26126832 0.84 ALDH1A1 (0.55) SMN1; SMN2HPGDTSHRL3MBTL1ALDH1A1
SCHEMBL26125439 0.84 ALDH1A1 (0.55) SMN1; SMN2HPGDTSHRL3MBTL1ALDH1A1
SCHEMBL31338454 0.84 CYP11B1 (0.46) SMN1; SMN2TSHRALDH1A1GHSRS1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213560-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF BNH RESEARCH CO., LTD. (KR) 2025-07-03 US disclosed
EP-4501911-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF BNH Research Co., Ltd. (KR) 2025-02-05 EP disclosed
CN-119343331-A Nitrogen-containing heterocyclic compound having phenyl group and use thereof BNH研究有限责任公司 2025-01-21 CN disclosed
WO-2023191469-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF 주식회사 비엔에이치리서치 2023-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213560-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF PNMT, BDNF, NLN SMN1; SMN2 185/4885HPGD 139/4885TSHR 4447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.